SEARCH

SEARCH BY CITATION

References

  • Anon (2000) Safety of meningococcal group C conjugate vaccines. Curr Probl Pharmacovigilance 26: 14.
  • Anon (2006) Update: Guillain–Barré syndrome among recipients of Menactra® meningococcal conjugate vaccine–United States, June 2005–September 2006. MMWR 55: 11201124.
  • Berron S, De La Fuente L, Martin E & Vazquez JA (1998) Increasing incidence of meningococcal disease in Spain associated with a new variant of serogroup C. Eur J Clin Microbiol Infect Dis 17: 8589.
  • Bogaert D, Hermans PW, Boelens H, Sluijter M, Luijendijk A, Rumke HC, Koppen S, Van Belkum A, De Groot R & Verbrugh HA (2005) Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children. Clin Infect Dis 40: 899902. Epub 2005 Feb 18.
  • Borrow R, Carlone GM, Rosenstein N et al. (2006) Neisseria meningitidis group B correlates of protection and assay standardization–International Meeting Report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 24: 50935107.
  • Bos JM, Rumke HC, Welte R, Spanjaard L, Van Alphen L & Postma MJ (2006) Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands. Pharmacoeconomics 24: 141153.
  • Brehony C, Jolley KA & Maiden MCJ (2006) Multilocus sequence typing for global surveillance of meningococcal disease. Fems Microbiol Rev 31: DOI: DOI: 10.1111/j.1574-6976.2006.00056.x
  • Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C & Vazquez JA (2004) Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 9: 1115.
  • Centers for Disease Control and Prevention (CDC). (2005). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR; 54(RR-7); 1–21.
  • Chief Medical Officer, Chief Nursing Officer, Chief Pharmacist. (2006). Important changes to the childhood immunisation programme. UK Department of Health 2006. PL CMO 1. URL http://www.dh.gov.uk/assetRoot/04/13/71/75/04137175.pdf [accessed on 18 August 2006].
  • De Greeff SC, De Melker HE, Spanjaard L, Schouls LM & Van Der Ende A (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25: 7980.
  • Dominguez A, Cardenosa N, Izquierdo C, Sanchez F, Margall N, Vazquez JA, Salleras L & Working Group on Meningococcal Disease in Catalonia. (2001) Prevalence of Neisseria meningitidis carriers in the school population of Catalonia, Spain. Epidemiol Infect 127: 425433.
  • Finne J, Leinonen M & Makela PH (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2: 355357.
  • Jodar L, Feavers IM, Salisbury D & Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet 359: 14991508.
  • Krizova P & Musilek M (1995) Changing epidemiology of meningococcal invasive disease in the Czech Republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37. Cent Eur J Public Health 3: 189194.
  • Larrauri A, Cano R, Garcia M & Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23: 40974100.
  • Maiden MC & Spratt BG (1999) Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 354: 615616.
  • Maiden MCJ, Stuart JM & on behalf of the UK Meningococcal Carriage Group. (2002) Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 18291830.
  • Miller E, Salisbury D & Ramsay M (2001) Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 (Suppl. 1): S58S67.
  • Mueller JE, Borrow R & Gessner BD (2006) Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines 5: 319336.
  • Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S & Martin D (2005) MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseriameningitidis serogroup B disease epidemic strain. Vaccine 23: 21912196.
  • Pavlopoulou ID, Daikos GL, Alexandrou H, Petridou E, Pangalis A, Theodoridou M & Syriopoulou VP (2004) Carriage of Neisseria meningitidis by Greek children: risk factors and strain characteristics. Clin Microbiol Infect 10: 137142.
  • Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13: 302317.
  • Peltola H, Makela PH, Elo O, Pettay O, Renkonen OV & Sivonen A (1976) Vaccination against meningococcal group A disease in Finland 1974–75. Scand J Infect Dis 8: 169174.
  • Perez-Trallero E, Vicente D, Montes M & Cisterna R (2002) Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis. Lancet 360: 953.
  • Ramsay ME, Andrews N, Kaczmarksi EB & Miller E (2001) Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357: 195196.
  • Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB & Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England. Br Med J 326: 365366.
  • Rosenstein NE, Perkins BA, Stephens DS et al. (1999) The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis 180: 18941901.
  • Ruedin HJ, Ess S, Zimmermann HP & Szucs T (2003) Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. Vaccine 21: 41454152.
  • Stein DM, Robbins J, Miller MA, Lin FY & Schneerson R (2006) Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? Vaccine 24: 221228.
  • Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD & Stephens DS (1997) Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 94: 271276.
  • Trotter CL & Edmunds WJ (2002) Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Br Med J 324: 809812.
  • Trotter CL & Edmunds WJ (2006) Reassessment of the cost-effectiveness of meningococcal serogroup C conjugate vaccines using dynamic models. Med Decis Making 26: 3847.
  • Trotter CL, Andrews NJ, Kaczmarski EB, Miller E & Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine four years after introduction. Lancet 364: 365367.
  • Trotter CL, Gay NJ & Edmunds WJ (2005) Dynamic models of meningococcal carriage, disease and the impact of serogroup C vaccination. Am J Epidemiol 162: 89100.
  • Trotter CL, Ramsay ME, Gray S, Fox A & Kaczmarski E (2006) No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 6: 616617.
  • Welte R, Trotter CL, Edmunds WJ, Postma M & Beutels P (2005) The role of economic modelling studies in vaccine decision making: focus on meningococcal C vaccination. Pharmacoeconomics 23: 855874.
  • Whalen CM, Hockin JC, Ryan A & Ashton F (1995) The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. J Am Med Assoc 273: 390394.
  • Yarwood J, Noakes K, Kennedy D, Campbell H & Salisbury D (2005) Tracking mothers attitudes to childhood immunisation 1991–2001. Vaccine 23: 56705687.